22
8
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1016L |
Aviptadil Acetate
醋酸阿肽地尔,阿肽地尔,Vasoactive Intestinal Peptide acetate salt |
RAAS; SARS-CoV | Endocrinology/Hormones; Microbiology/Virology |
Aviptadil Acetate (Vasoactive Intestinal Peptide acetate salt) 是模拟血管活性肠多肽类似物,具有血管舒张效应。它可诱导肺血管舒张并抑制血管 SMC 的增殖和血小板聚集。它可用于研究 SARS-CoV-2 引起的肺纤维化、肺动脉高压和呼吸衰竭。 | |||
TP1016 |
Aviptadil
Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine),阿肽地尔 |
||
Aviptadil (INN) is an analog of vasoactive intestinal polypeptide (VIP) for the treatment of erectile dysfunction. | |||
T80866 |
VIP(Guinea pig) TFA
Vasoactive Intestinal Peptide, guinea pig TFA |
||
VIP Guinea pig TFA,作为一种胃肠激素,兼具神经递质功能,能够刺激胚胎生长,起到营养和有丝分裂因子的作用。 | |||
TP1627L |
Prepro VIP (111-122), human acetate
Prepro VIP (111-122), human acetate(123025-94-5 free base) |
Others | Others |
Prepro VIP (111-122), human acetate(123025-94-5 free base) 是一种前血管活性肠多肽 (VIP) 衍生肽,对应于残基 111-122。 | |||
TP2103L |
[D-p-Cl-Phe6,Leu17]-VIP acetate
|
Others | Others |
[D-p-Cl-Phe6,Leu17]-VIP acetate 是一种竞争性和选择性的血管活性肠肽 (VIP) 受体拮抗剂 (IC50 = 125.8 nM)。 | |||
TP1283L |
VIP(6-28)(human, rat, porcine, bovine) acetate
|
Others | Others |
VIP(6-28)(human, rat, porcine, bovine) acetate 是外源性血管活性肠肽 (VIP) 受体对颈上神经节 (SCG) 中 cAMP 作用的拮抗剂。 | |||
TP2103 |
[D-p-Cl-Phe6,Leu17]-VIP
|
||
Selective vasoactive intestinal peptide (VIP) receptor antagonist (IC50 = 125.8 nM). Displays no activity on glucagon, secretin or GRF receptors. | |||
TP1627 |
Prepro VIP (111-122), human
|
||
Prepro VIP (111-122), human is a prepro-vasoactive intestinal polypeptide (VIP)–derived peptide, corresponding to residues 111-122. | |||
TP1283 |
VIP(6-28)(human, rat, porcine, bovine)
|
||
VIP(6-28)(human, rat, porcine, bovine) is a potent antagonist that effectively counteracts the effects of exogenous vasoactive intestinal peptide (VIP) on cyclic adenosine monophosphate (cAMP) signaling. | |||
TP1635 |
Prepro VIP (81-122), human
|
||
Prepro VIP (81-122), human is a prepro-vasoactive intestinal polypeptide (VIP) derived peptide, corresponding to residues 81-122. | |||
T36635 |
[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human)
[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) |
||
[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) 是GRF的 类似物,是一种血管活性肠肽 (VIP) 拮抗剂。 | |||
T83195 |
Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27)
|
||
Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27),是一种血管活性肠肽,起到VIP1受体拮抗剂的作用。 | |||
TP1054 |
PACAP (1-38), human, ovine, rat TFA
Pituitary Adenylate Cyclase Activating Polypeptide 38 (TFA) |
||
PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP), | |||
T36428 |
PACAP-related Peptide (human) (trifluoroacetate salt)
|
PACAP | GPCR/G Protein |
PACAP-related peptide (PRP) is an endogenous 29-amino acid peptide that belongs to the secretin/glucagon superfamily of peptides, which includes secretin , glucagon , glucagon-like peptide-1 , GLP-2 , and pituitary adenylate cyclase-activating polypeptide . It is expressed in normal human pancreas and adrenal gland tissue and in some tumors that produce vasoactive intestinal peptide (VIP). PRP (1-29) is secreted by CHO-K1 cells that express human recombinant preproPACAP. | |||
T80876 |
Vasomera
|
||
Vasomera是一種穩定的長效血管活性腸肽(VIP)激動劑,主要作用於G蛋白偶聯的VPAC2受體,適用於與肌肉營養不良症相關的心肌病研究。 | |||
T80069 |
PACAP (6-27) (human, ovine, rat)
Pituitary adenylate cyclase-activating peptide (6-27) |
||
PACAP (6-27) (human, ovine, rat) 是一种对PACAP受体具有拮抗作用的化合物,可以抑制犬肾上腺对外源性VIP的反应。此化合物在心血管疾病和神经系统疾病研究中展现出应用潜力。 | |||
T78003 |
[D-p-Cl-Phe6,Leu17]-VIP TFA
|
||
[D-p-Cl-Phe6,Leu17]-VIP TFA,为竞争性及选择性血管活性肠肽(VIP)受体拮抗剂,其IC50为125.8 nM。该化合物针对胰高血糖素、促胰液素和GRF受体均不表现活性。 | |||
T82217 |
Helospectin I
|
||
Helospectin I属于血管活性肠肽(VIP)家族的一种神经肽,能够引起血管扩张,具有抗高血压效果,可用于降低血压。该化合物最早是从Heloderma suspectum蜥蜴的唾液腺毒液中分离得到。 | |||
T82216 |
Helospectin II
|
||
Helospectin II,一种属于血管活性肠肽(VIP)家族的神经肽,具备血管扩张作用及抗高血压活性,能够降低血压。该化合物最初从蜥蜴Heloderma suspectum的唾液腺毒液中分离得到。 | |||
T81571 |
PACAP (1-38) free acid TFA
|
||
PACAP (1-38) free acid TFA,一种内源性神经肽,能有效促进胃窦运动,增强体液蛋白分泌,同时抑制胃泌素释放。此外,它刺激血管活性肠肽、胃泌素释放肽和P物质的释放,并通过RACK1增强N-甲基-D-天门冬氨酸受体功能及脑源性神经营养因子表达。 | |||
T78035 |
[K15,R16,L27]VIP(1-7)/GRF(8-27) acetate
|
||
[K15,R16,L27]VIP(1-7)/GRF(8-27)(acetate)为[K15,R16,L27]VIP(1-7)/GRF(8-27)的醋酸盐形态,作为VIP1激动剂,与人类和大鼠的肠血管活性肽1 (VIP 1) 及大鼠的肠血管活性肽2 (VIP 2) 的结合IC50值分别为2 nM、1 nM和30000 nM。 | |||
T81572 |
PACAP (1-38) free acid
|
||
PACAP (1-38) free acid 是一种具有多重生物功能的内源性神经肽,主要作用包括刺激胃窦运动、增进体液蛋白分泌、抑制胃泌素分泌,以及促进血管活性肠肽、胃泌素释放肽和P 物质的释放。此外,PACAP (1-38) free acid 通过与RACK1互作,可以增强N-甲基-D-天门冬氨酸受体的功能并促进脑源性神经营养因子的表达。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-03597 |
VIP Protein, Human, Recombinant (His)
PHM27,vasoactive intestinal peptide |
Human | HEK293 Cells |
VIP, or vasoactive intestinal peptide, is a neuropeptide of 28 amino acid residues that belongs to a glucagon/secretin superfamily, and it exerts its actions through three G-protein-coupled receptors (PAC1, VPAC1, and VPAC2). VIP is synthesized by trophoblast cells; it regulates trophoblast cell function and interaction with the major immune cell populations present in the pregnant uterus. | |||
TMPY-01120 |
VPAC2 Protein, Human, Recombinant (mFc)
VPCAP2R,PACAP-R-3,VIP-R-2,vasoactive intestinal... |
Human | HEK293 Cells |
VIP and PACAP receptor 2, or VIPR2 encodes the VPAC2 receptor, which binds both VIP and PACAP. VPAC2 is expressed throughout the central nervous system and the periphery. Mutations in the VIPR2 homolog in the mouse cause hypoactivity, as well as disruptions in circadian rhythm. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. | |||
TMPK-01501 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)
MHC,Hepatitis B virus,HBV |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01491 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HBV,Hepatitis B virus |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01505 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi), Biotinylated
E7,MHC,HPV16 |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01492 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi)
Hepatitis B virus,HBV,MHC |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01504 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein, Human, MHC (His & Avi)
MHC,HPV16,E7 |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01506 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi)
HPV16,E7,MHC |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. |